<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01890174</url>
  </required_header>
  <id_info>
    <org_study_id>HD-OCT-DR-2010-2</org_study_id>
    <nct_id>NCT01890174</nct_id>
  </id_info>
  <brief_title>Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation</brief_title>
  <official_title>Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DataMed Devices Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Carl Zeiss Meditec, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the repeatability and reproducibility of the
      Cirrus HD-OCT measurements of drusen area and volume.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single site study. Ocular history and examination will be conducted on
      consented subjects to determine further participation in the study. The study will be divided
      into two phases. In Phase 1, the inter-device variability of Cirrus HD-OCT measurements of
      drusen area and volume will be determined. In Phase 2, the inter-operator variability of
      Cirrus HD-OCT measurements of drusen area and volume will be determined. In each of these
      phases, the Macular Cube 200 x 200 scan and the Macular Cube 512 x 128 scan will be
      evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of variation for area (mm^2) of RPE elevation measurements in the central 3 mm circle.</measure>
    <time_frame>Single visit observation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variation for volume (mm^3) of RPE elevation measurements in the central 3 mm circle.</measure>
    <time_frame>Single visit observation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Coefficient of variation for area (mm^2) of RPE elevation measurements in the central 5 mm circle.</measure>
    <time_frame>Single visit observation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Coefficient of variation for volume (mm^3) of RPE elevation measurements in the central 5 mm circle.</measure>
    <time_frame>Single visit observation</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">54</enrollment>
  <condition>Dry AMD With Macular Drusen</condition>
  <arm_group>
    <arm_group_label>AMD with macular drusen</arm_group_label>
    <description>Patients diagnosed with dry AMD with macular drusen</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females 50 years of age or older diagnosed to have dry AMD with macular
             drusen.

          2. Drusen should not be combined with other lesions such as geographic atrophy (GA) or
             choroidal neovascularization.

          3. Able and willing to make the required study visits.

          4. Able and willing to give consent and follow study instructions.

        Exclusion Criteria:

          1. History of retinal surgery, laser photocoagulation, and/or radiation therapy to the
             eye.

          2. Evidence of other retinal diseases of the eye, including wet AMD, diabetic
             retinopathy, diabetic macular edema, or significant vitreomacular traction.

          3. Thick media opacity or inability to fixate that precludes obtaining acceptable scans.

          4. Concomitant use of hydrochloroquine or chloroquine.

          5. Unable to make the required study visits.

          6. Unable to give consent or follow study instructions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Wieland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern California Retina Vitreous Associates Medical Group, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schmitz-Valckenberg S, Fleckenstein M, Scholl HP, Holz FG. Fundus autofluorescence and progression of age-related macular degeneration. Surv Ophthalmol. 2009 Jan-Feb;54(1):96-117. doi: 10.1016/j.survophthal.2008.10.004. Review.</citation>
    <PMID>19171212</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2013</study_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

